Advances in the development of new biologics in inflammatory bowel disease

Bella Ungar, Uri Kopylov*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Biologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infliximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently being developed for both anti-TNF-naïve and -resistant patients. These include anti-integrins (vedolizumab and etrolizumab), a JAK inhibitor (tofacitinib) and an anti-anti-interleukin (IL)-23 and IL-12 antibody (ustekinumab), among additional drugs in development. The following review discusses the indications, efficacy and safety issues for these novel medications.

Original languageEnglish
Pages (from-to)243-248
Number of pages6
JournalAnnals of Gastroenterology
Issue number3
StatePublished - 2016


  • Biologics
  • Crohn’s disease
  • Inflammatory bowel disease
  • Therapy
  • Ulcerative colitis


Dive into the research topics of 'Advances in the development of new biologics in inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this